GlobalData on MSN3d
Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.CcrFU5Zy.js ...
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis ...
Pharm Exec11h
Mim8 Demonstrates Promising Results in Pediatric Patients with Hemophilia A
Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.
PharmiWeb13h
Phase 3 FRONTIER3 interim analysis data presented…
Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...
The Pharma Letter3d
Novo Nordisk adds to Mim8 data set ahead of filing
Danish pharma major Novo Nordisk has announced interim results from the Phase III FRONTIER3 trial of 70 children with ...
PMLiVE3d
Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study
Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...
FierceBiotech3d
Novo Nordisk adds pediatric data to bulging bag of evidence on near-approval hemophilia A prospect
Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...
Mena FN3d
Novo Nordisk A/S: Once-Weekly Mim8 Is Well-Tolerated And Efficacious In Children Living With Haemophilia A With And Without Inhibitors
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026.
BioSpace3d
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...